- Home
- DVAX vs STEW Comparison
DVAX vs STEW Comparison
Compare DVAX & STEW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVAX
- STEW
- Stock Information
- Founded
- DVAX 1996
- STEW 1972
- Country
- DVAX United States
- STEW United States
- Employees
- DVAX N/A
- STEW N/A
- Industry
- DVAX Biotechnology: Pharmaceutical Preparations
- STEW Investment Managers
- Sector
- DVAX Health Care
- STEW Finance
- Exchange
- DVAX Nasdaq
- STEW Nasdaq
- Market Cap
- DVAX 1.5B
- STEW 1.5B
- IPO Year
- DVAX 2004
- STEW N/A
- Fundamental
- Price
- DVAX $12.21
- STEW $16.25
- Analyst Decision
- DVAX Buy
- STEW
- Analyst Count
- DVAX 2
- STEW 0
- Target Price
- DVAX $22.00
- STEW N/A
- AVG Volume (30 Days)
- DVAX 3.3M
- STEW 84.5K
- Earning Date
- DVAX 11-07-2024
- STEW 01-01-0001
- Dividend Yield
- DVAX N/A
- STEW 3.71%
- EPS Growth
- DVAX N/A
- STEW N/A
- EPS
- DVAX 0.15
- STEW 1.44
- Revenue
- DVAX $260,810,000.00
- STEW N/A
- Revenue This Year
- DVAX $23.13
- STEW N/A
- Revenue Next Year
- DVAX $19.60
- STEW N/A
- P/E Ratio
- DVAX $80.80
- STEW $10.34
- Revenue Growth
- DVAX N/A
- STEW N/A
- 52 Week Low
- DVAX $9.74
- STEW $11.97
- 52 Week High
- DVAX $15.01
- STEW $14.94
- Technical
- Relative Strength Index (RSI)
- DVAX 52.22
- STEW 60.97
- Support Level
- DVAX $11.61
- STEW $16.19
- Resistance Level
- DVAX $13.74
- STEW $16.46
- Average True Range (ATR)
- DVAX 0.52
- STEW 0.19
- MACD
- DVAX 0.09
- STEW 0.06
- Stochastic Oscillator
- DVAX 32.80
- STEW 81.64
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
About STEW SRH Total Return Fund Inc.
SRH Total Return Fund, Inc. is a non-diversified closed-end management investment company. The company's investment objective is to seek total return. Its fund utilizes a bottom-up, value-driven investment process to identify securities of good quality businesses trading below estimated intrinsic value. The Funds are available as an actively-managed closed-end fund, an actively managed ETF and a passively-managed ETF.